INTRODUCTION
Invariant natural killer T (iNKT) cells are a subset of evolutionarily conserved innate-like T cells that recognize antigen presented by CD1d. They are defined by their invariant T-cell receptor, 1 containing a Va24JaQ rearrangement preferentially paired with Vb11 in humans, and Va14Ja18 paired with Vb8.2 in mice. The representation of iNKT cells is highly variable between individuals, and in human peripheral blood they range from 0.001% up to 41% of the T-cell compartment. An important characteristic of iNKT cells is their capacity to rapidly produce cytokines, such as interferon (IFN)-g, interleukin (IL)-4, and tumor necrosis factor (TNF)-a, upon recognition of glycolipid antigens presented by CD1d. iNKT cells are highly reactive to CD1d presenting the sphingolipid a-galactosylceramide (a-GalCer), 1 microbial glycolipids from different species, e.g., Borrelia burgdorferi 2 and Sphingomonas spp, 2 and endogenous mammalian b-linked glycolipids, including b-glucosylceramide (b-GlcCer). 3 Most recently, a prominent member of the gut microbiome, Bacteroides spp, has been found to produce an a-linked sphingolipid structurally related a-GalCer, which similarly modulates NKT function. 4 This diverse reactivity provides iNKT cells with immune modulating capacities, and they have important roles in the resolution or pathology of microbial and viral infections, cancers, and autoimmune diseases. [5] [6] [7] iNKT cells develop in the thymus from precursor CD4 þ CD8 þ thymocytes, and are positively selected by CD1d molecules expressed on CD4 þ CD8 þ thymocytes. [8] [9] [10] [11] CD1d is highly expressed in the thymus, 12 and the endogenous CD1d ligand b-GlcCer is readily detected in mouse thymus, 3 indicating that b-GlcCer presented by CD1d could be involved in iNKT cell selection. Whereas iNKT cells are present in the human fetal thymus at higher frequencies at the start of the second trimester, their representation gradually declines with gestational age, and they are present at very low frequency in the post-natal thymus. This indicates that a relatively large part of the thymic iNKT cell output occurs during early fetal development.
In the fetal thymus, iNKT cells are largely CD4 þ , and only a small fraction express CD161. 12, 14 In full-term cord blood, iNKT cells remain largely CD4 þ , and approximately 50% express CD161. In addition, a majority of the full-term cord blood iNKT cells express CCR7 and CD62L, but interestingly lack expression of CD45RA (normally associated with a naïve T-cell phenotype). 14, 15 In contrast to fetal thymus and term cord blood, a majority of the iNKT cells in adult blood lack expression of CD4, are almost uniformly CD161 þ , and only a small proportion express CD62L or CCR7. This indicates that iNKT cell differentiation is characterized by gradual loss of CD4 expression, increased expression of CD161, and loss of CD62L and CCR7. [16] [17] [18] This model of iNKT cell differentiation has also been corroborated in longitudinal studies of cord blood transplantations, where the first iNKT cells to develop are largely CD4 þ CD161 À CCR7 þ CD62L þ . These cells subsequently loose expression of CD4, CD62L, and CCR7, and acquire expression of CD161, as well as CD56 and CD94/ NKG2A. 15, 19 The differentiation of iNKT cells after cord blood transplantation is also associated with increased production of IFN-g and IL-4, indicating that the phenotypic differentiation is also coupled to functional maturation. 15 During normal pregnancies, the fetus is believed to be developing in a sterile environment. In mice, the presence of commensal bacteria early after birth controls the accumulation of iNKT cells in the colon, and decreases susceptibility to experimentally induced mucosal inflammation. 20 In addition, iNKT cells in germ-free mice are less differentiated, and respond poorly upon antigen stimulation, 21 indicating that commensal bacteria can drive the differentiation and functional maturation of iNKT cells. However, it remains unknown to what extent the microflora affects human iNKT cell development and function.
Although human iNKT cells are detected in the fetal thymus early during gestation, it remains unknown when, and to what extent they migrate to peripheral lymphoid and non-lymphoid organs, whether fetal iNKT cells differentiate in the peripheral organs, and if they are functional. Here, we show that human fetal iNKT cells are present in the small intestine, lung, spleen, and mesenteric lymph nodes (MLNs) during the second trimester. There was a striking accumulation of iNKT cells in the small intestine, which contained an approximately fivefold higher frequency of iNKT cells compared with other organs. Small intestinal iNKT cells exhibited characteristics of differentiated cells, with more frequent expression of CD161, IFN-g production, and a lower proliferative capacity in response to a-GalCer stimulation. Conversely, the iNKT cells in lymph nodes and spleen exhibited a less differentiated phenotype, with lower frequency of CD161 expression, poor IFN-g production, and higher proliferative capacity. Taken together, our data suggest that differentiation and functional maturation of human iNKT cells can occur in the absence of a commensal flora in the small intestine, and that intestinal iNKT cells have the potential to have an immunoregulatory role in the developing human fetus, as well as directly after birth.
RESULTS iNKT cells are present in human fetal lymphoid and non-lymphoid peripheral tissues
We have previously shown that iNKT cells can be detected at low frequency in the human fetal thymus. 12 To investigate which other tissues contained iNKT cells in the developing fetus, we analyzed mononuclear cell suspensions from fetal tissues between gestational weeks 16 and 22 by flow cytometry. iNKT cells were defined as CD1d tetramer þ (loaded with the a-GalCer analog PBS57) CD3
þ TCR Va24 þ cells (Figure 1a and Supplementary Figure S1 online). We could detect iNKT cells in fetal lung, small intestine, spleen, MLNs, and less consistently in fetal liver (Figure 1a, b) . Minimal background staining was observed with the unloaded CD1d tetramer, demonstrating the specificity of the staining (Supplementary Figure S2) . Strikingly, in the small intestine, iNKT cells comprised up to 5.4% (average 1.21%) of the total T cells, whereas iNKT cells in lung, spleen, and MLN comprised less than 0.5% (average 0.19%, 0.27%, and 0.16%, respectively) of the total T cells ( Figure 1b) . As a reference, iNKT cells in adult peripheral blood mononuclear cells (PBMCs) on average made up 0.21% of the total T cells (Figure 1b) . The frequency of iNKT cells increased with gestational age in the small intestine ( Figure 1c ) and spleen (Figure 1d) , whereas no such correlation was observed in MLNs (data not shown). It should, however, be noted that the minimum age of MLN was gestational week 18, because of the scarcity of these structures at earlier gestational ages.
CD1d is expressed in the fetal small intestinal architecture
Given the high frequency of iNKT cells in the fetal small intestine, we investigated whether CD1d was expressed in this tissue. CD1d was distinctly expressed in the epithelium of the small intestine (Figure 2b, c) . Interestingly, CD1d was also localized between epithelial cells, clustered around the tips of the villi. CD1d staining was also observed in the Peyer's patches of the small intestine ( Figure 2a) . No background staining was observed from the IgG1 isotype control section (Figure 2d-f) .
Fetal iNKT cells can differentiate in utero
Given the distinct accumulation of iNKT cells in the small intestine, compared with spleen, lymph node, and lung, we next analyzed whether there was also a distinct pattern of differentiation associated with the different tissues. iNKT cell differentiation is characterized by a transition from CD4 þ to CD4 À cells, in addition to increased expression of CD161 and lower expression of CD62L and CCR7. iNKT cells in the spleen and MLN were almost exclusively CD4 þ CD8 À (Figure 3a) , indicative of an immature phenotype. In contrast, a significantly smaller proportion of the iNKT cells in the small intestine were CD4 þ CD8 À compared with fetal spleen and MLN (Figure 3a) , indicating that a small fraction of the iNKT cells in the small intestine had differentiated into CD4 À phenotypes. However, fetal iNKT cells in all organs investigated displayed a less differentiated phenotype compared with adult iNKT cells, which were predominantly CD4 Figure 3a) . To further address differences between iNKT cells in the intestine, spleen, and MLN, we analyzed the expression of a range of markers associated with iNKT cell differentiation. Interestingly, a much smaller fraction of iNKT cells in the small intestine expressed CD161 and CD45RO, compared with iNKT cells from the spleen and MLN (Figure 3b, c) . Furthermore, iNKT cells in the small intestine lacked expression of CD62L and CCR7, whereas these receptors were expressed by a large proportion of the iNKT cells in the spleen and MLN, thus indicating that the iNKT cells in the small intestine were more differentiated than those in lymphoid tissues (Figure 3b and c) . In addition, a fraction of iNKT cells in the small intestine also expressed CD56, as well as NKG2A, expression of these proteins was undetectable on iNKT cells in fetal spleen and MLN (Figure 3b and c and Supplementary Figure S3B) . Whereas iNKT cells from all fetal tissues and adult blood uniformly expressed CD127 (IL-7Ra) and CD122 (IL-2Rb) (Figure 3b) , a much larger fraction of the fetal iNKT cells expressed CD25 (IL-2Ra) compared with adult blood iNKT cells (Figure 3b and c) , indicating that fetal iNKT cells might be more responsive to low doses of IL-2. CD25 was, however, expressed at an intermediate level compared with fetal regulatory T cells, which express high levels of CD25 (Supplementary Figure S3) . 22 To further dissect the differentiation of iNKT cells in different tissues, we analyzed the co-expression of CD4 and CD161, as well as the co-expression Figure 4b , upper panels). Interestingly, the small intestine also contained a higher proportion of CD45RO þ CD62L À conventional T cells, indicating that T cells in this tissue are more differentiated in general ( Figure 4b , lower panels). Taken together, our data show that iNKT cells with a differentiated phenotype accumulate in the small intestine, indicating that iNKT cells can differentiate in utero in the absence of commensal microflora.
Fetal iNKT cells in the small intestines have gained the capacity to produce IFN-c
Adult iNKT cells in human peripheral blood rapidly produce large amounts of cytokines, including TNF-a and IFN-g after stimulation with a-GalCer. However, it remains unknown whether fetal iNKT cells in peripheral organs are functionally mature. Germ-free mice, lacking a commensal microflora, have been shown to have a diminished production of TNF-a and IFN-g compared with specific pathogen-free mice after stimulation with a-GalCer. 21 This opens the possibility that human fetal iNKT cells could be similarly functionally immature as a consequence of lack of priming from a commensal microflora. To assess the cytokine-producing potential of fetal iNKT cells, mononuclear cell suspensions from the spleen, MLN, and small intestine were stimulated with a-GalCer followed by staining for IFN-g and TNF-a. Minimal background cytokine production in the absence of stimulation was observed (data not shown). Stimulation with a-GalCer resulted in a strong TNF-a production, comparable to that of the adult PBMC iNKT cells (Figure 5a ). When comparing the three fetal tissues, iNKT cells in the small intestine and spleen expressed significantly higher levels of TNF-a compared with those from MLN (Pr0.05, Figure 5b) . A much higher frequency of the iNKT cells in the small intestine produced IFN-g compared with those in spleen and MLN, and the frequency of IFN-g þ iNKT cells in the small intestine approached the levels seen in adult blood iNKT cells (Figure 5a, b) . Given that the IFN-g responses to a-GalCer stimulation were lower in the lymphoid organs, we sought to examine whether IFN-g production by iNKT cells from spleen and MLN would be more robust in response to TCR-independent activation mechanisms. We therefore stimulated mononuclear cells from fetal spleen, MLN, and small intestine, as well as adult blood, with phorbol myristate acetate/ionomycin. iNKT cells in the small intestine produced IFN-g much more frequently than those in the spleen and MLN (Supplementary Figure S4) . Together, these data indicate that small intestinal fetal iNKT cells have gained a mature effector function, including IFN-g production.
High-proliferative capacity of fetal iNKT cells in lymphoid tissues
Given the differential ability of fetal iNKT cells from diverse tissues to produce cytokines, we next sought to investigate the proliferative potential of these cells. To assess the proliferative capacity, mononuclear cell suspensions were labeled with cell tracer violet and cultured with a-GalCer and IL-2 ( Figure 6 ). After 6-7 days of culture in the presence of a-GalCer and IL-2, the vast majority of iNKT cells from all fetal tissues assessed had Figure S5) , indicating that their proliferation was not mediated by CD1d/TCR-induced activation. This was also apparent in the spleen, MLN, and adult PBMCs (Supplementary Figure  S5) . Although iNKT cells from all tissues proliferated extensively, as analyzed by the dilution of the cell trace dye to background levels, it remained possible that the iNKT cells proliferated beyond the complete dilution of the cell tracker dye, leading to differences in the proliferative response between different tissues. When analyzing the frequency of iNKT cells from the different tissues after 6-7 days of culture in IL-2 and aGalCer, there was a marked increase of CD1d-tetramer þ cells from spleen and MLN (410-fold) compared with small intestine (o5-fold; Figure 6b-d) , indicating that iNKT cells in the spleen and MLN had a greater ability to proliferate compared with those from the small intestine. It, however, remained possible that the lower degree of iNKT cell expansion in the small intestine was due to a greater expansion of other T cells in this tissue, thus partially masking the expansion of iNKT cells. This in part can be seen with the increase in the frequency of Va24 þ non-iNKT in the presence of IL-2 þ / À a-GalCer at days 6-7 ( Figure 6b , middle and lower panels). Conversely, frequencies of Va24 þ non-iNKT cells in the spleen, MLN, and adult PBMCs remain similar to those at day 0 (Figure 6b) . Furthermore, the non-iNKT CD3 þ population in the small intestine undergoes a greater number of divisions compared with the spleen (Supplementary Figure S6) . Alternatively, iNKT cells in the small intestine may undergo apoptosis or downregulate CD3/TCR to a greater degree than those in the spleen and MLN, and thus confounding the analysis. However, in all organs with culture in the presence of a-GalCer, the expression of CD3/TCR was similar (Supplementary Figure  S5 , lower panel), indicating that the lower level of expansion was not solely due to a selective downregulation of the TCR on iNKT cells from small intestine. In addition, we could detect an increased frequency of CD1d-tetramer þ cells among the dead cells from small intestine compared with spleen (Supplementary Figure S7) . present in the MLN, however, the frequency of live MLN iNKT was greater. Finally, by comparing the frequency of iNKT cells in small intestine, spleen, and MLN after stimulation with IL-2 alone and IL-2 þ a-GalCer, the increase in iNKT cell frequency was greater in both the spleen and MLN compared with the small intestine (Figure 6b) , indicating that the iNKT cells in the small intestine indeed have a lower proliferative capacity. After day 7 of a-GalCer culture, increased CD161 expression was observed in splenic iNKTs (Supplementary Figure S8A) , indicating maturation after culture with exogenous antigens. In the spleen and MLN, the composition of iNKT cells with respect to expression of CD4 and CD8 remained largely unaltered, indicating that all subsets had proliferated (Supplementary Figure S8B and C). After 6-7 days of stimulation with a-GalCer and IL-2, the frequency of CD4 þ CD8 À iNKT cells was increased in the small intestine, whereas the frequency of CD4 þ CD8 þ and CD4 À CD8 À iNKT cells decreased, indicating that CD4 þ CD8 À iNKT cells in the intestine had a proliferative advantage (Supplementary Figure S8B , gray circles). These observations suggest that fetal iNKT cells require glycolipid antigens to proliferate, and that iNKT cells in the spleen and MLN have a higher capacity to proliferate than their small intestinal counterparts.
DISCUSSION
In mice, iNKT cells develop in the thymus and exit as an immature subset. 23 Likewise, studies of human cord blood, maternal decidua, and fetal thymic organ cultures have indicated that full iNKT cell maturation occurs in the periphery. 12,13,24-26 However, it remains unknown when and to what extent fetal iNKT cells migrate to peripheral lymphoid and non-lymphoid organs, whether fetal iNKT cells differentiate in the peripheral organs, and if they are functional. Here, we show that human fetal iNKT cells are found in peripheral non-lymphoid and lymphoid organs before birth, and that the frequency of iNKT cells in the spleen and small intestine increases with gestational age. Strikingly, there was a pronounced accumulation of iNKT cells in the human fetal small intestine that exhibited a differentiated and functionally mature profile, as compared with iNKT cells found in the secondary lymphoid tissues, spleen, and MLN.
The consistent detection of iNKT cells in spleen, MLN, and small intestine indicates that these organs are among the first sites where iNKT cells traffic after leaving the thymus. In contrast to murine iNKT cells, where enrichment is observed in the liver (up to 50% of hepatic lymphocytes), 27, 28 we did not detect significant numbers of iNKT cells in human fetal liver. Instead, iNKT cell frequencies were high in the human fetal small intestine, up to 5.4% of CD3 þ cells at gestational week 23. In the adult gastrointestinal tract (colon), CD1d-restricted, a-GalCer-responsive NKT cells comprise o0.5% of lamina propria lymphocytes (reviewed in van Dieren et al. 29 ). It is unclear whether iNKT cells in the small intestine remain at higher frequencies or retract after birth. However, several murine studies have demonstrated the importance of commensal microflora and CD1d in iNKT cell expansions. 20, 21, 30 However, our data suggests that human iNKT cells mature and gain function in the small intestine well before birth and the colonization by the normal microflora.
The strikingly mature profile of fetal small intestinal iNKT cells raises the question of what potential roles they may be playing in the human fetal gut. Our study shows that iNKT cells in the small intestine are poised to respond to ligands presented on the non-classical, MHC-class I-like molecule CD1d, to a more robust extent than their lymphoid counterparts. The strong IFN-g responses elicited and lack of lymphoid homing receptors on small intestinal iNKT cells suggests that this cell subset may be playing a potential effector role that is tissue specific. The ability of fetal small intestinal iNKT cells to produce IFN-g in a CD1d-restricted manner may be beneficial in utero or in neonates, given their immature adaptive immune system, 31 and their potential to be exposed to a range of pathogenic microbes and viruses, including Group B Streptococcus and Streptococcus Pneumoniae. 32, 33 Indeed, recent studies have demonstrated that such bacterial species have been shown to contain glycolipids that activate iNKTs in a CD1d-dependent manner. 34, 35 Speculatively, small intestinal iNKT cells may serve as an innate defense line in the fetus and neonate, and production of T H 1 cytokines may help activate other effector innate immune cells such as mucosal NK cells and macrophages. 36 Although iNKT cells are well documented to produce a range of pro-and anti-inflammatory cytokines, only T H 1 cytokines were investigated in our study. Further analyses of other cytokines after stimulation with a-GalCer and additional iNKT cell ligands, e.g., OCH2, b-GlcCer, GSL-1, 37 may determine whether other iNKT-associated cytokines, such IL-4, IL-22, IL-13, IL-17, are produced by fetal small intestinal and lymphoid iNKT cells.
The question remains as to how this population of peripheral organ iNKT cells matures compared with their lymphoid tissue counterparts. In murine studies, it has been shown that CD1d is critical for iNKT cell maturation. 38, 39 In line with this, we show that CD1d is expressed on the epithelium of the small intestine. It is tempting to speculate that the more mature phenotype of small intestinal iNKT cells could be driven by the presentation of endogenous glycolipids on CD1d. Indeed, recent studies in mice have demonstrated that the endogenous glycolipid, bGlcCer, can be isolated from spleen and thymus. 3 Furthermore, b-GlcCer has been found to be important in activating iNKT cells via microbial danger signals induced from stimulation of Toll-like receptors. 3 Such activation in the context of the human fetus raises the question as to whether the fetal environment is completely devoid of microbial products, despite lacking a commensal microflora. Several recent studies have suggested that non-pathogenic bacterial DNA can be detected in the placenta and also in the meconium (the first stool) of neonates. 40, 41 In addition, in mothers who are given probiotic treatment during pregnancy, increased expression of Toll-like receptor-related genes is observed in the meconium of neonates delivered by cesarian sections. 42 Bacterial products, rather than viable microbes, could thus potentially be contributing to the maturation of iNKT cells in the fetal small intestine. In addition to microbial products, cytokines such as IL-7 and IL-15 have been shown to be important for the effector maturation of innate cell subsets including both NK and iNKT cells. [43] [44] [45] [46] Indeed, we have previously shown that low doses of IL-7 support the maintenance and maturation of human fetal thymic iNKT cells. 12 In our current study, human fetal iNKT cells had high expression of IL-7Ra (CD127). Furthermore, fetal iNKT cells also highly expressed the IL-2Rb (CD122) subunit component of the IL-15 receptor. However, further studies would be required to investigate if human fetal lymphoid iNKT cells cultured in the presence of IL-15 resulted in maturation phenotype similar to small intestinal iNKT cells, or if the fetal small intestinal microenvironment has elevated levels of IL-15 compared with lymphoid tissues. Although small intestinal iNKT cells have a mature phenotype and cytokine profile, they did not expand ex vivo to the same extent as the less differentiated iNKT cells from the fetal spleen and MLN. This could be due in part to cell death of small intestinal iNKT cells in culture. In human and murine models, intestinal epithelial/stromal cells provide IL-7 for T cells, 47, 48 hence, the ex vivo culture conditions in the proliferation experiments may not support the survival of these cells. Our data from the proliferation experiments also suggests that small intestinal iNKT cells are different to the lymphoid iNKT cells, given that iNKT cells in the small intestine are responsive to IL-2 stimulation in the absence of a-GalCer. In addition, our data also show that conventional T cells in the small intestine proliferate extensively in the presence of IL-2, and therefore may dilute out the true expansion of iNKT cells in the small intestine in response to a-GalCer. Further delaying the addition of IL-2 to ex vivo cultures may ameliorate the background proliferation by conventional T cells and allow for more accurate assessment of a-GalCer-driven expansion. A caveat of our proliferation studies is the lack of data regarding the ex vivo proliferation of cell tracer-labeled fetal iNKTs from the MLN in response to IL-2 alone. Nevertheless, our data with unlabeled cells from the MLN suggests that iNKT cells do not proliferate in the presence of IL-2 alone, given that no difference in iNKT frequency at day 6/7 was observed when compared with day 0; however, the extent of conventional T cells proliferation is unknown. Indeed, from healthy neonatal mice, it is has been shown that IL-2 mRNA transcripts and protein can be isolated from the gut and not from the spleen or lymph nodes, which supports our data regarding the proliferation of conventional T cells in response to IL-2 alone in the small intestine. 49 Analyses of mRNA transcripts in situ from human fetal tissue for IL-2 expression would confirm this.
In summary, we have shown that human iNKT cells mature and accumulate in peripheral organs, particularly in the small intestine, during fetal development. This finding further demonstrates that iNKT cells in the human fetal immune system can differentiate and functionally mature before birth, and before the establishment of the normal intestinal microbiota. Tissue preparation. The small intestine was cut into 6 cm lengths, and the meconium was removed. Small intestinal tissue was then incubated for 20 min in Hanks Buffered Saline Solution (1 Â ; GIBCO, Carlsbad, CA) containing fungizone (1 Â ; Invitrogen, Carlsbad, CA) at 37 1C. Small intestine, lung, and liver were subsequently transferred to a cell culture dish, cut into small pieces, incubated for 50 min at 37 1C in digestion media (RPMI; GIBCO), 0.25 mg ml À 1 Collagenase Type II (Sigma-Aldrich, Steinheim, Germany), fungizone (1 Â ), and HEPES (Invitrogen)) with vortexing every 10 min. After the incubation, the cell suspensions were passed through 70-mm plastic cell strainers and washed twice with cold complete media containing 10% fetal calf serum. To obtain single-cell suspensions from the spleen, the tissue was gently pressed through a 70-mm cell strainer. The cell suspensions were subsequently centrifuged on a ficoll/paque density gradient to isolate mononuclear cells. MLNs were dissected from intact mesentery using fine pincer forceps, incubated in digestion media for 30 min at 37 1C, washed twice in cold complete media, and subsequently passed through a 70-mm cell strainer to obtain a single-cell suspensions. 6 mononuclear cells were resuspended in 1 ml of complete media alone or containing 1 mg ml À 1 a-GalCer, and incubated at 37 1C for 8 h, with addition of Brefeldin A after 2 h. Responses to phorbol myristate acetate/ionomycin were analyzed by incubating 2 Â 10 6 cells in 1 ml of complete medium alone, or containing 2 ml Leukocyte Activation Cocktail (phorbol myristate acetate/ionomycin with Brefeldin A, BD Biosciences) overnight at 37 1C. Cells were subsequently washed in complete media, surface stained to identify iNKT cells, fixed with cytofix/cytoperm (BD Biosciences) for 20 min at 4 1C, washed twice with perm/wash buffer (BD Biosciences), incubated in perm/wash buffer with anti-IFN-g -V450 (Clone B27) and anti-TNF-a-Alexa Fluor 700 (Clone MAb11) for 30 min at 4 1C, and finally washed twice in perm/wash buffer before analysis by flow cytometry.
METHODS
iNKT cell expansion. Mononuclear cell suspensions from the small intestine, spleen, MLN, and adult PBMCs were labeled with 5 mM cell trace violet (Invitrogen) in RPMI containing HEPES buffer, L-glutamine and penicillin/streptomycin for 20 min at 37 1C. The cells were subsequently washed twice in complete medium with 10% fetal calf serum. After labeling, 4 Â 10 6 cells were cultured in 2 ml of complete media in a 24-well plate, with the addition of 100 ng ml À 1 of a-GalCer on day 0. On day 1, 50 U ml À 1 of IL-2 (Roche, Basel, Switzerland) was added to the culture. The cultures were analyzed after 6-7 days of culture, with addition of fresh media with IL-2 and a-GalCer after 3-4 days.
Immunohistochemistry. Small intestinal tissue was fixed overnight at 4 1C in 4% electron microscopy grade paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA). The tissue was then dehydrated with ethanol and then xylene before paraffin embedding. Fivemicrometer sections of tissue were de-paraffinized and rehydrated with a decreasing concentration of ethanol. After heat-induced antigen retrieval in citrate buffer and peroxidase blocking with H 2 O 2 , the sections were stained with a 1:1000 dilution of anti-CD1d (clone NOR3.2, AbCam, Cambridge, UK) or isotype-matched control overnight at 4 1C. Slides were then visualized with the EnVision þ System-HRP by using 3,3
0 -diaminobenzidine as a substrate (Dako, Glostrup, Denmark). Images were acquired on a Leica DM6000B using ImagePro version 6 (Leica, Wetzlar, Germany).
Statistical analyses. GraphPad Prism 6 (GraphPad software, San Diego, CA) was used to perform statistical analyses. Statistical comparisons among the different fetal tissue groups were performed using the one-way analysis of variance non-parametric Kruskal-Wallis test, with a confidence level of 95%. A Po0.05 value was considered significant. Adult PBMCs were not included in the statistical comparisons. AUTHOR CONTRIBUTIONS L.L. was involved in designing the study, collecting tissue, performing experiments, analyzing data, making figures, and writing the paper. M.I. was involved in collecting tissue and performing experiments. J.M. was involved in making the figures and writing the manuscript. J.K.S. was involved in designing the study and writing the manuscript. D.F.N. was involved in designing the study and writing the manuscript.
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